Your browser doesn't support javascript.
loading
[Biologic agents in COPD management]. / Place des biothérapies dans la BPCO.
Gueçamburu, M; Zysman, M.
Affiliation
  • Gueçamburu M; Service des maladies respiratoires, CHU de Bordeaux, Centre François-Magendie, hôpital Haut-Lévêque, hôpital Haut Lévèque, avenue de Magellan, 33604 Pessac, France. Electronic address: marina.guecamburu@live.fr.
  • Zysman M; Service des maladies respiratoires, CHU de Bordeaux, Centre François-Magendie, hôpital Haut-Lévêque, hôpital Haut Lévèque, avenue de Magellan, 33604 Pessac, France; U1045, CIC 1401, Univ-Bordeaux, Centre de Recherche cardio-thoracique de Bordeaux, 33604 Pessac, France.
Rev Mal Respir ; 41(2): 127-138, 2024 Feb.
Article in Fr | MEDLINE | ID: mdl-38129268
ABSTRACT
Chronic obstructive pulmonary disease (COPD) is a frequently occurring disease entailing high morbidity and mortality, and relevant therapeutic resources are limited. As is the case with asthma, the current trend consists in the phenotyping of COPD patients so as to develop personalized medicine tailored to a given individual's inflammatory profile. The aim of this review is to summarize the role of biologic agents in the management of COPD, taking into consideration not only COPD pathophysiology, but also the previously published studies and the relatively encouraging prospects for the future.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Asthma / Biological Products / Pulmonary Disease, Chronic Obstructive Limits: Humans Language: Fr Journal: Rev Mal Respir / Rev. mal. respir / Revue des maladies respiratoires Year: 2024 Document type: Article Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Asthma / Biological Products / Pulmonary Disease, Chronic Obstructive Limits: Humans Language: Fr Journal: Rev Mal Respir / Rev. mal. respir / Revue des maladies respiratoires Year: 2024 Document type: Article Country of publication: